KDM6A Recombinant Rabbit mAb (S-1728-51)
Lysine-specific demethylase 6A,Histone demethylase UTX,Ubiquitously-transcribed TPR protein on the X chromosome,Ubiquitously-transcribed X chromosome tetratricopeptide repeat protein,[histone H3]-trimethyl-L-lysine(27) demethylase 6A,UTX
分享产品介绍 FAQs 评论(0)
宿主来源
Rabbit抗原名称
KDM6A分子别名
Lysine-specific demethylase 6A; Histone demethylase UTX; Ubiquitously-transcribed TPR protein on the X chromosome; Ubiquitously-transcribed X chromosome tetratricopeptide repeat protein; [histone H3]-trimethyl-L-lysine(27) demethylase 6A; UTX免疫原
Synthetic Peptide细胞定位
NucleusAccession
O15550克隆号
S-1728-51抗体类型
Recombinant mAb抗体同种型
IgG反应种属 ?
Hu, Ms, Rt阳性样本
PANC-1, HEK-293, K562, mouse spleen纯化方式
Protein A浓度
0.5 mg/ml标记
Unconjugated性状
Liquid缓冲体系
PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300储存条件
12 months from date of receipt / reconstitution, -20 °C as supplied
应用
IHC-P ?
WB
稀释度
应用 稀释度 推荐种属 WB 1:1000 Hu, Ms IHC-P 1:200 Hu, Ms, Rt
KDM6A is a histone demethylase that belongs to the KDM6 family, specifically targeting di- and tri-methylated histone H3 lysine 27 (H3K27) to remove these modifications, thereby affecting gene expression and transcriptional regulation. KDM6A is frequently mutated in various cancers and functions as a tumor suppressor. Its loss of function or mutations have been implicated in the development and progression of cancers such as multiple myeloma, esophageal squamous cell carcinoma, clear cell renal cell carcinoma, medulloblastoma, adenoid cystic carcinoma, urothelial bladder cancer, T-cell acute lymphoblastic leukemia, and pancreatic cancer. In prostate cancer, KDM6A mutations are associated with the progression to lethal castration-resistant disease. KDM6A is important for the differentiation of embryonic stem cells and the development of various tissues. Its mutations are known to cause Kabuki syndrome, which is characterized by distinct facial features, skeletal anomalies, and intellectual disability. Apart from its demethylase activity, KDM6A also modulates chromatin reprogramming and mediates transcriptional activation/repression in a ligand protein-dependent manner, affecting various physiological and pathological processes.
免疫印迹
WB result of KDM6A Recombinant Rabbit mAb
Primary antibody: KDM6A Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: THP-1 whole cell lysate 20 µg
Lane 2: PANC-1 whole cell lysate 20 µg
Lane 3: HEK-293 whole cell lysate 20 µg
Lane 4: K562 whole cell lysate 20 µg
Negative control: THP-1 whole cell lysate
Weak expression: PANC-1 whole cell lysate
Secondary antibody: Goat Anti-Rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution Predicted MW: 154 kDa
Observed MW: 180 kDaWB result of KDM6A Recombinant Rabbit mAb
Primary antibody: KDM6A Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: mouse spleen lysate 20 µg
Secondary antibody: Goat Anti-Rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution Predicted MW: 154 kDa
Observed MW: 180 kDa
免疫组化
IHC shows positive staining in paraffin-embedded human ovarian cancer. Anti-KDM6A antibody was used at 1/200 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.
IHC shows positive staining in paraffin-embedded mouse testis. Anti-KDM6A antibody was used at 1/200 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.
IHC shows positive staining in paraffin-embedded rat testis. Anti-KDM6A antibody was used at 1/200 dilution, followed by a HRP Polymer for Mouse & Rabbit IgG (ready to use). Counterstained with hematoxylin. Heat mediated antigen retrieval with Tris/EDTA buffer pH9.0 was performed before commencing with IHC staining protocol.
组织表达图谱
Expression of KDM6A in tumor tissue.
Expression of KDM6A in human tissue.
Expression of KDM6A in mouse & rat tissue.
FAQs
我们一般不推荐客户回收利用抗体。 因为抗体使用之后缓冲体系已经发生改变，不同客户在回收抗体的保存条件上也会有差异，所以抗体回收使用效果无法保证。另外，我们对一批抗体回收验证测试，测试结果显示不同抗体可回收次数不同，一般效价越高的抗体，可重复使用的次数越多，客户可根据实验情况来确定
评论(0)